이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

OraSure Technologies 관리

관리 기준 확인 2/4

OraSure Technologies' CEO는 Carrie Eglinton Manner, Jun2022 에 임명되었습니다 의 임기는 2.17 년입니다. 총 연간 보상은 $ 6.70M, 10.8% 로 구성됩니다. 10.8% 급여 및 89.2% 보너스(회사 주식 및 옵션 포함). 는 € 4.55M 가치에 해당하는 회사 주식의 1.58% 직접 소유합니다. 4.55M. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 3.5 년입니다.

주요 정보

Carrie Eglinton Manner

최고 경영자

US$6.7m

총 보상

CEO 급여 비율	10.8%
CEO 임기	2.3yrs
CEO 소유권	1.6%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Carrie Eglinton Manner 의 보수는 OraSure Technologies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$27m
Mar 31 2024	n/a	n/a	US$23m
Dec 31 2023	US$7m	US$721k	US$54m
Sep 30 2023	n/a	n/a	US$49m
Jun 30 2023	n/a	n/a	US$44m
Mar 31 2023	n/a	n/a	US$30m
Dec 31 2022	US$7m	US$377k	-US$17m

보상 대 시장: Carrie 의 총 보상 ($USD 6.70M )은 German 시장( $USD 1.21M ).

보상과 수익: Carrie 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Carrie Eglinton Manner (49 yo)

2.3yrs

테뉴어

US$6,701,767

보상

Ms. Carrie Eglinton Manner serves as President, Chief Executive Officer & Director of OraSure Technologies, Inc. since June 04, 2022. She joined OraSure Technologies, Inc. on June 04, 2022. She serves as a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Carrie Eglinton Manner	President	2.3yrs	US$6.70m	1.58% $ 4.5m
Kenneth McGrath	Chief Financial Officer	2.1yrs	US$1.53m	0.41% $ 1.2m
Kathleen Weber	Chief Product Officer	11.8yrs	US$1.67m	0.40% $ 1.1m
Michele Anthony	Senior VP	5.9yrs	데이터 없음	0.14% $ 389.1k
Rafal Iwasiow	Vice President of Science	1.7yrs	데이터 없음	데이터 없음
Jason Plagman	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Stefano Taucer	General Counsel & Corporate Secretary	2.2yrs	데이터 없음	데이터 없음
David Rappaport	Senior Vice President Corporate Development	2.7yrs	데이터 없음	데이터 없음
Amy Steigerwalt	Senior Vice President of Human Resources	2.7yrs	데이터 없음	데이터 없음
Zachary Wert	Senior Vice President of Global Operations	2.2yrs	데이터 없음	데이터 없음
Trace Custer	Senior Vice President of Quality & Regulatory	1.8yrs	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: EP3 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Carrie Eglinton Manner	President	2.3yrs	US$6.70m	1.58% $ 4.5m
David Shulkin	Independent Director	4.4yrs	US$170.00k	0.081% $ 230.2k
Mara Aspinall	Independent Chair of the Board	7.3yrs	US$228.99k	0.15% $ 436.6k
Nancy Gagliano	Independent Director	2.8yrs	US$183.12k	0.11% $ 300.6k
Robert McMahon	Independent Director	1.2yrs	US$135.93k	0.057% $ 162.7k
John Kenny	Independent Director	no data	데이터 없음	0.031% $ 88.8k
Lelio Marmora	Independent Director	4.3yrs	US$170.00k	0.081% $ 231.7k

2.8yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: EP3 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

OraSure Technologies 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

OraSure Technologies, Inc. Appoints John P. Kenny as New Member of the Board, Member of the Nominating and Corporate Governance Committee

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

Chief Financial Officer recently bought €460k worth of stock

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Recent updates

OraSure Technologies, Inc. Appoints John P. Kenny as New Member of the Board, Member of the Nominating and Corporate Governance Committee

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.008 loss per share (vs US$0.065 loss in 2Q 2023)

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2024

OraSure Technologies, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Shareholder dilution

OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings released: US$0.048 loss per share (vs US$0.37 profit in 1Q 2023)

New minor risk - Shareholder dilution

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$0.73 (vs US$0.25 loss in FY 2022)

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Investor sentiment improves as stock rises 22%

OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023

Third quarter 2023 earnings released: EPS: US$0.15 (vs US$0.073 in 3Q 2022)

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 27%

New major risk - Share price stability

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings released: US$0.065 loss per share (vs US$0.26 loss in 2Q 2022)

OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

Investor sentiment improves as stock rises 18%

Chief Financial Officer recently bought €460k worth of stock

Investor sentiment deteriorates as stock falls 20%

Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023

First quarter 2023 earnings released: EPS: US$0.37 (vs US$0.28 loss in 1Q 2022)

OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.25 loss per share (vs US$0.32 loss in FY 2021)

OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023

OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Third quarter 2022 earnings released: EPS: US$0.073 (vs US$0.21 loss in 3Q 2021)

OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022

Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration

OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store

OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Independent Director recently bought €200k worth of stock

Independent Chairman of the Board recently bought €53k worth of stock

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.019 loss in 2Q 2021)

OraSure Technologies, Inc. Announces CFO Changes

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2022

OraSure Technologies, Inc. to Report Q2, 2022 Results on Aug 09, 2022

OraSure Technologies, Inc. Announces Executive Changes

OraSure Technologies LaunchesNewProduct for Microbiome Researchers to Study DNA and RNA

OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell 2000 Value-Defensive Index

OraSure Technologies, Inc. Announces Resignation of Agnieszka M. Gallagher as Executive Vice President, General Counsel and Chief Compliance Officer, Effective June 25, 2022

OraSure Technologies, Inc. Appoints Carrie Eglinton Manner as President, Effective June 4, 2022

OraSure Technologies, Inc. Announces That Its InteliSwab® Covid-19 Rapid Tests Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.053 profit in 1Q 2021)

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

OraSure Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Orasure Technologies, Inc. Announces Inteliswab® Covid-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New Inteliswab® Connect Reporting App

OraSure Technologies, Inc. Updates Revenue Guidance for the Fourth Quarter of 2021

High number of new directors

High number of new directors

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.015 profit in 3Q 2020)

OraSure Technologies, Inc. to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

CFO & Principal Accounting Officer Roberto Cuca has left the company

Orasure Technologies, Inc. Provides Revenue Guidance for the Third Quarter and Fiscal Year 2021

Second quarter 2021 earnings released: US$18.95 loss per share (vs US$0.16 loss in 2Q 2020)

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board